# AnnotationID, ClassType, DocCharOnset(incl), DocCharOffset(excl), Text, Meta, Instances
0, Journal, 0, 19, "Curr Med Res Opin .", "", "<http://ctro/data#Publication_54551> <http://ctro/data#hasJournal> \"Curr Med Res Opin .\"."
1, PublicationYear, 20, 24, "2008", "", "<http://ctro/data#Publication_54551> <http://ctro/data#hasPublicationYear> \"2008\"."
83, Title, 90, 194, "Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes .", "", "<http://ctro/data#Publication_54551> <http://ctro/data#hasTitle> \"Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes .\"."
2, Sitagliptin, 113, 124, "sitagliptin", "", 
3, Metformin, 142, 151, "metformin", "", 
4, Type2Diabetes, 177, 192, "type 2 diabetes", "", 
5, Author, 195, 200, "Raz I", "", "<http://ctro/data#Publication_54551> <http://ctro/data#hasAuthor> \"Raz I\"."
6, Author, 209, 215, "Chen Y", "", "<http://ctro/data#Publication_54551> <http://ctro/data#hasAuthor> \"Chen Y\"."
7, Author, 218, 222, "Wu M", "", "<http://ctro/data#Publication_54551> <http://ctro/data#hasAuthor> \"Wu M\"."
8, Author, 225, 234, "Hussain S", "", "<http://ctro/data#Publication_54551> <http://ctro/data#hasAuthor> \"Hussain S\"."
9, Author, 237, 247, "Kaufman KD", "", "<http://ctro/data#Publication_54551> <http://ctro/data#hasAuthor> \"Kaufman KD\"."
10, Author, 250, 261, "Amatruda JM", "", "<http://ctro/data#Publication_54551> <http://ctro/data#hasAuthor> \"Amatruda JM\"."
11, Author, 264, 274, "Langdon RB", "", "<http://ctro/data#Publication_54551> <http://ctro/data#hasAuthor> \"Langdon RB\"."
12, Author, 277, 285, "Stein PP", "", "<http://ctro/data#Publication_54551> <http://ctro/data#hasAuthor> \"Stein PP\"."
13, Author, 288, 294, "Alba M", "", "<http://ctro/data#Publication_54551> <http://ctro/data#hasAuthor> \"Alba M\"."
14, Israel, 424, 430, "Israel", "", "<http://ctro/data#Population_54586> <http://ctro/data#hasCountry> <http://ctro/data#Israel>."
100, ObjectiveDescription, 445, 691, "The purpose of this study was to evaluate the efficacy and safety of sitagliptin as an add - on to metformin therapy in patients with moderately severe ( hemoglobin A ( 1c ) > or = 8 . 0 % and < or = 11 . 0 % ) type 2 diabetes mellitus ( T2DM ) .", "", "<http://ctro/data#ClinicalTrial_54567> <http://ctro/data#hasObjectiveDescription> \"The purpose of this study was to evaluate the efficacy and safety of sitagliptin as an add - on to metformin therapy in patients with moderately severe ( hemoglobin A ( 1c ) > or = 8 . 0 % and < or = 11 . 0 % ) type 2 diabetes mellitus ( T2DM ) .\"."
15, Sitagliptin, 514, 525, "sitagliptin", "", 
22, Precondition, 532, 689, "add - on to metformin therapy in patients with moderately severe ( hemoglobin A ( 1c ) > or = 8 . 0 % and < or = 11 . 0 % ) type 2 diabetes mellitus ( T2DM )", "", "<http://ctro/data#Population_54586> <http://ctro/data#hasPrecondition> \"add - on to metformin therapy in patients with moderately severe ( hemoglobin A ( 1c ) > or = 8 . 0 % and < or = 11 . 0 % ) type 2 diabetes mellitus ( T2DM )\"."
16, Metformin, 544, 553, "metformin", "", 
17, HbA1c, 599, 618, "hemoglobin A ( 1c )", "", 
18, Percentage, 632, 633, "%", "", 
19, Percentage, 652, 653, "%", "", 
20, Type2Diabetes, 656, 680, "type 2 diabetes mellitus", "", "<http://ctro/data#ClinicalTrial_54567> <http://ctro/data#analysesHealthCondition> <http://ctro/data#Type2Diabetes>."
21, Type2Diabetes, 683, 687, "T2DM", "", 
101, Multicenter, 733, 746, "multinational", "", "<http://ctro/data#ClinicalTrial_54567> <http://ctro/data#hasCTDesign> <http://ctro/data#Multicenter>."
23, Randomized, 749, 759, "randomized", "", "<http://ctro/data#ClinicalTrial_54567> <http://ctro/data#hasCTDesign> <http://ctro/data#Randomized>."
103, Placebo, 762, 769, "placebo", "", 
24, Parallel, 785, 801, "parallel - group", "", "<http://ctro/data#ClinicalTrial_54567> <http://ctro/data#hasCTDesign> <http://ctro/data#Parallel>."
25, DoubleBlind, 804, 818, "double - blind", "", "<http://ctro/data#ClinicalTrial_54567> <http://ctro/data#hasCTDesign> <http://ctro/data#DoubleBlind>."
26, NumberPatientsCT, 838, 841, "190", "", "<http://ctro/data#ClinicalTrial_54567> <http://ctro/data#hasNumberPatientsCT> \"190\"."
27, Type2Diabetes, 856, 860, "T2DM", "", 
29, Metformin, 894, 903, "metformin", "", 
30, DoseValue, 918, 929, "> or = 1500", "", 
31, mg, 930, 932, "mg", "", 
32, Interval, 935, 938, "day", "", 
33, Randomized, 957, 967, "randomized", "", 
34, Sitagliptin, 994, 1005, "sitagliptin", "", "<http://ctro/data#Medication_54661> <http://ctro/data#hasDrug> <http://ctro/data#Sitagliptin>."
35, DoseValue, 1006, 1009, "100", "", "<http://ctro/data#Medication_54661> <http://ctro/data#hasDoseValue> \"100\"."
36, mg, 1010, 1012, "mg", "", "<http://ctro/data#Medication_54661> <http://ctro/data#hasDoseUnit> <http://ctro/data#mg>."
37, Frequency, 1013, 1023, "once daily", "", "<http://ctro/data#Intervention_54642> <http://ctro/data#hasFrequency> \"once daily\"."
38, Placebo, 1027, 1034, "placebo", "", "<http://ctro/data#Medication_54668> <http://ctro/data#hasDrug> <http://ctro/data#Placebo>."
39, Metformin, 1046, 1055, "metformin", "", 
40, Duration, 1060, 1068, "30 weeks", "", "<http://ctro/data#ClinicalTrial_54567> <http://ctro/data#hasCTduration> \"30 weeks\"."
41, HbA1c, 1142, 1161, "hemoglobin A ( 1c )", "", 
42, HbA1c, 1164, 1174, "HbA ( 1c )", "", 
43, TimePoint, 1186, 1200, "after 18 weeks", "", 
44, Sitagliptin, 1204, 1215, "sitagliptin", "", 
45, FastingPlasmaGlucose, 1274, 1296, "fasting plasma glucose", "", "<http://ctro/data#Endpoint_54810> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#FastingPlasmaGlucose>."
46, FastingPlasmaGlucose, 1299, 1302, "FPG", "", 
51505, EndPointDescription, 1309, 1355, "2 - hour ( 2 - h ) postprandial plasma glucose", "", 
170, PostprandialPlasmaGlucose, 1328, 1355, "postprandial plasma glucose", "", 
171, PostprandialPlasmaGlucose, 1358, 1361, "PPG", "", 
172, TimePoint, 1367, 1375, "18 weeks", "", 
47, HbA1c, 1382, 1392, "HbA ( 1c )", "", 
173, TimePoint, 1396, 1404, "30 weeks", "", 
48, HbA1c_target, 1454, 1474, "HbA ( 1c ) < 7 . 0 %", "", 
132, Percentage, 1473, 1474, "%", "", 
49, Sitagliptin, 1505, 1516, "Sitagliptin", "", 
50, HbA1c, 1539, 1549, "HbA ( 1c )", "", "<http://ctro/data#Endpoint_54594> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c>."
51, FastingPlasmaGlucose, 1552, 1555, "FPG", "", 
51504, EndPointDescription, 1562, 1571, "2 - h PPG", "", "<http://ctro/data#EndPointDescription_54600> <http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://ctro/data#EndPointDescription>. <http://ctro/data#Endpoint_54599> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#EndPointDescription_54600>."
51500, PostprandialPlasmaGlucose, 1568, 1571, "PPG", "", 
52, Placebo, 1588, 1595, "placebo", "", 
77, PvalueDiff, 1602, 1613, "p < 0 . 001", "", "<http://ctro/data#DiffBetweenGroups_54842> <http://ctro/data#hasPvalueDiff> \"p < 0 . 001\". <http://ctro/data#DiffBetweenGroups_54851> <http://ctro/data#hasPvalueDiff> \"p < 0 . 001\". <http://ctro/data#DiffBetweenGroups_54860> <http://ctro/data#hasPvalueDiff> \"p < 0 . 001\"."
53, HbA1c, 1641, 1651, "HbA ( 1c )", "", 
106297, DiffGroupAbsValue, 1656, 1663, "- 1 . 0", "", "<http://ctro/data#DiffBetweenGroups_54842> <http://ctro/data#hasDiffGroupAbsValue> \"- 1 . 0\"."
55, Percentage, 1664, 1665, "%", "", "<http://ctro/data#Endpoint_54594> <http://ctro/data#hasBaselineUnit> <http://ctro/data#Percentage>."
145, TimePoint, 1674, 1689, "18 and 30 weeks", "", 
146, TimePoint, 1681, 1689, "30 weeks", "", 
57, Sitagliptin, 1756, 1767, "sitagliptin", "", 
58, HbA1c_target, 1777, 1797, "HbA ( 1c ) < 7 . 0 %", "", "<http://ctro/data#Endpoint_54604> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#HbA1c_target>."
134, Percentage, 1796, 1797, "%", "", 
149, TimePoint, 1798, 1821, "by the end of the study", "", "<http://ctro/data#Outcome_54869> <http://ctro/data#hasTimePoint> \"by the end of the study\". <http://ctro/data#Outcome_54896> <http://ctro/data#hasTimePoint> \"by the end of the study\"."
59, PercentageAffected, 1824, 1830, "22 . 1", "", "<http://ctro/data#Outcome_54869> <http://ctro/data#hasPercentageAffected> \"22 . 1\"."
60, PercentageAffected, 1838, 1843, "3 . 3", "", "<http://ctro/data#Outcome_54896> <http://ctro/data#hasPercentageAffected> \"3 . 3\"."
61, PvalueDiff, 1848, 1859, "p < 0 . 001", "", "<http://ctro/data#DiffBetweenGroups_54923> <http://ctro/data#hasPvalueDiff> \"p < 0 . 001\"."
62, Sitagliptin, 1864, 1875, "Sitagliptin", "", 
175, ObservedResult, 1899, 2067, "Compared with placebo , sitagliptin had a neutral effect on body weight and did not significantly increase the risk of hypoglycemia or gastrointestinal adverse events .", "", "<http://ctro/data#Outcome_54932> <http://ctro/data#hasObservedResult> \"Compared with placebo , sitagliptin had a neutral effect on body weight and did not significantly increase the risk of hypoglycemia or gastrointestinal adverse events .\". <http://ctro/data#Outcome_54959> <http://ctro/data#hasObservedResult> \"Compared with placebo , sitagliptin had a neutral effect on body weight and did not significantly increase the risk of hypoglycemia or gastrointestinal adverse events .\". <http://ctro/data#Outcome_54986> <http://ctro/data#hasObservedResult> \"Compared with placebo , sitagliptin had a neutral effect on body weight and did not significantly increase the risk of hypoglycemia or gastrointestinal adverse events .\"."
64, Placebo, 1913, 1920, "placebo", "", 
63, Sitagliptin, 1923, 1934, "sitagliptin", "", 
65, BodyWeight, 1959, 1970, "body weight", "", "<http://ctro/data#Endpoint_54609> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#BodyWeight>."
66, Hypoglycemia, 2018, 2030, "hypoglycemia", "", "<http://ctro/data#Endpoint_54614> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#Hypoglycemia>."
67, GastrointestinalProblem, 2034, 2065, "gastrointestinal adverse events", "", "<http://ctro/data#Endpoint_54619> <http://ctro/data#hasEndoPointDescription> <http://ctro/data#GastrointestinalProblem>."
176, ConclusionComment, 2082, 2294, "Addition of sitagliptin 100 mg once daily to ongoing metformin therapy was well - tolerated and resulted in significant glycemic improvement in patients with moderately severe T2DM who were treated for 30 weeks .", "", "<http://ctro/data#ClinicalTrial_54567> <http://ctro/data#hasConclusionComment> \"Addition of sitagliptin 100 mg once daily to ongoing metformin therapy was well - tolerated and resulted in significant glycemic improvement in patients with moderately severe T2DM who were treated for 30 weeks .\"."
69, Sitagliptin, 2094, 2105, "sitagliptin", "", 
70, DoseValue, 2106, 2109, "100", "", 
71, mg, 2110, 2112, "mg", "", 
72, Frequency, 2113, 2123, "once daily", "", 
73, Metformin, 2135, 2144, "metformin", "", 
74, Type2Diabetes, 2258, 2262, "T2DM", "", 
75, Duration, 2284, 2292, "30 weeks", "", 
76, PMID, 2337, 2345, "18194595", "", "<http://ctro/data#Publication_54551> <http://ctro/data#hasPMID> \"18194595\"."
